<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941148</url>
  </required_header>
  <id_info>
    <org_study_id>LANT_001</org_study_id>
    <secondary_id>EudraCT Number: 2007-006109-26</secondary_id>
    <nct_id>NCT00941148</nct_id>
  </id_info>
  <brief_title>Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin</brief_title>
  <official_title>Impact of Insulin (I.)Glargine Compared to NPH I. and to I. Detemir in Combination With Metformin on Prandial ß-cell Function and Overall Metabolic Control in Type 2 Diabetic Patients With Insufficient Metabolic Control During OAD Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ikfe-CRO GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IKFE Institute for Clinical Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ikfe-CRO GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to show that treatment with Glargine will lead to an improvement in
      beta cell function especially within times of maximal beta cell stress occurring after a
      meal. For this reason three different standardized test meals (breakfast, lunch, dinner) will
      be performed and the postprandial secretion of intact proinsulin levels will be measured.
      These measurements will be performed with patients treated in combination with metformin and
      insulin glargine versus metformin plus NPH insulin (within the core study) and if significant
      difference is observed, with a third treatment arm with metformin plus insulin detemir.

      Hypothesis is that the area under the curve (AUC) intact proinsulin levels within 2 hours
      after test meal dinner of metformin plus insulin glargin differs from AUC intact proinsulin
      levels of metformin plus NPH insulin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postprandial dynamics of intact proinsulin secretion after standardized test meals (AUC for two hours after dinner)</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC for intact proinsulin levels for two hours after a standardized test meal (breakfast and lunch)</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>increase of intact proinsulin after breakfast (BF), lunch (LU) and dinner (DI)</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of exogenous insulin vs. endogenous insulin (measurements of glargine, NPH Insulin, detemir and human insulin levels)</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial endothelial function measured as postischaemic response in LDF measurements (after BF, LU, DI)</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial change in and AUC for hs CRP (after BF, LU, DI)</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial change in and AUC for ADMA (after BF, LU, DI)</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial increase in and AUC for glucose levels (after BF, LU, DI)</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FBG</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 8-point BG profiles</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching the treatment goal</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dosage per kg body weight to reach treatment goal</measure>
    <time_frame>12 +/- 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetic Patients</condition>
  <condition>Insufficient Metabolic Control</condition>
  <condition>OAD Treatment</condition>
  <arm_group>
    <arm_group_label>Insulin glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glargine, dose individually adapted to reach treatment goal (FBG &lt; 100 mg/dL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPH Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPH Insulin, dose individually adapted to reach treatment goal (FBG &lt; 100 mg/dL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin detemir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin detemir, dose individually adapted to reach treatment goal (FBG &lt; 100 mg/dL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargin</intervention_name>
    <arm_group_label>Insulin glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH insulin</intervention_name>
    <arm_group_label>NPH Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin detemir</intervention_name>
    <arm_group_label>Insulin detemir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>metformin (2000 mg/day)</description>
    <arm_group_label>Insulin glargine</arm_group_label>
    <arm_group_label>NPH Insulin</arm_group_label>
    <arm_group_label>Insulin detemir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes mellitus according to the ADA criteria

          -  HbA1c between 6.5% and 8.5%

          -  Individually optimized combination therapy with metformin in combination with
             sulfonylurea in a stable dosage within the last 3 months

          -  Age between 40 and 75 years

          -  Fasting intact proinsulin level &gt; 7 pmol/Land &lt; 20 pmol/Lat screening

        Exclusion Criteria:

          -  Type 1 Diabetes mellitus

          -  Pre-Treatment with insulin within the last 3 months prior to screening

          -  Pre-Treatment with PPARy-agonists (glitazones) within the last 3 months prior to
             screening

          -  Major micro- or macrovascular complications as judged by the investigator

          -  BMI &gt; 40 kg/m²

          -  Hypokalemia (K &lt; 3.5 mmol /L)

          -  History of drug or alcohol abuse

          -  Anamnestic history of hypersensitivity to the study drugs or to drugs with similar
             chemical structures

          -  History of severe or multiple allergies

          -  Treatment with any other investigational drug within 3 months prior to screening

          -  Progressive fatal disease

          -  History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT
             and/or ASAT &gt; 3 times the normal reference range), renal (creatinine &gt; 1.3 mg/dL in
             women and &gt; 1.7 mg/dL in men), neurological, psychiatric and/or haematological disease
             as judged by the investigator

          -  Pregnancy or breast feeding

          -  Sexually active women of childbearing potential not actively and consistently
             practicing birth control by using a medically accepted device or therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ikfe GmbH, Clinic Department</name>
      <address>
        <city>Mainz</city>
        <state>RLP</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>July 16, 2009</last_update_submitted>
  <last_update_submitted_qc>July 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Thomas Forst, MD</name_title>
    <organization>ikfe GmbH</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

